Abstract: A self-balancing wheel assembly includes a rim, a tire mounted to the rim and defining an inflatable chamber between the rim and the tire, and a valve mounted to the rim for inflating and deflating the tire. The valve includes a housing having a channel therein extending between an outer surface of the housing and the chamber. The valve includes a stopper movable within the channel between an open and a closed position for allowing and blocking fluid flow through the channel, the stopper being narrower in width than the channel. The assembly further includes balancing media in the chamber, the balancing media comprising solid particles sized sufficiently large to inhibit passage of the solid particles past the stopper. The assembly can be used in wheels having integral TPMS modules, and having aluminum valve stems connected to the modules and short, nickel plated valve cores mounted in the stems.

Abstract: A communications network has multiple resource-allocation layers and incorporates a management structure for allocating resources to allocate resources requested by a first layer of said layers from a second of said layers. At a first layer, the management structure provides an indication to a second layer of the required resources that are to be allocated from the second layer. The second layer automatically offers the required resource together with a condition for use of those resources. This condition includes a notional price factor which is dependent on current demand. Under the control of the manager, the first layer determines if the condition for use of the offered resources is acceptable and, if so, automatically accepts the offered resources from the second layer. In a preferred embodiment, ingress to an underlying multi-wavelength transport layer of the network is controlled via a virtual port which allocates traffic to real ports one for each wavelength supported by the transport layer.

Abstract: The present invention relates generally to the enantiomers of para-hydroxy-milnacipran or congeners thereof. Biological assays revealed that racemic para-hydroxy-milnacipran is approximately equipotent in inhibiting serotonin and norepinephrine uptake (IC50=28.6 nM for norepinephrine, IC50=21.7 nM for serotonin). Interestingly, (+)-para-hydroxy-milnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50=10.3 nM for norepinephrine, IC50=22 nM for serotonin). In contrast, (?)-para-hydroxy-milnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrin uptake (IC50=88.5 nM for norepinephrine, IC50=40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the aforementioned compounds. In certain embodiments, the compounds of the present invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient.

Abstract: A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.

Abstract: A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.

Abstract: The clearances between an array of turbine blades and its surrounding blade track may be controlled by an expansion control material system supporting the blade tracks. The blade track support hoop is placed in tension by the expansion control material placed therein and the expansion control material is placed in compression.

Abstract: The present invention relates generally to the enantiomers of para-hydroxy-milnacipran or congeners thereof. Biological assays revealed that racemic para-hydroxy-milnacipran is approximately equipotent in inhibiting serotonin and norepinephrine uptake (IC50=28.6 nM for norepinephrine, IC50=21.7 nM for serotonin). Interestingly, (+)-para-hydroxy-milnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50=10.3 nM for norepinephrine, IC50=22 nM for serotonin). In contrast, (−)-para-hydroxy-milnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrin uptake (IC50=88.5 nM for norepinephrine, IC50=40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the aforementioned compounds. In certain embodiments, the compounds of the present invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient.

Abstract: A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.

Abstract: A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. These levels help to avoid stimulation of the cholinergic effects on the CNS.

Abstract: A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.

Abstract: A communications network has multiple resource-allocation layers and incorporates a management structure for allocating resources to allocate resources requested by a first layer of said layers from a second of said layers. At a first layer, the management structure provides an indication to a second layer of the required resources that are to be allocated from the second layer. The second layer automatically offers the required resource together with a condition for use of those resources. This condition includes a notional price factor which is dependent on current demand. Under the control of the manager, the first layer determines if the condition for use of the offered resources is acceptable and, if so, automatically accepts the offered resources from the second layer. In a preferred embodiment, ingress to an underlying multi-wavelength transport layer of the network is controlled via a virtual port which allocates traffic to real ports one for each wavelength supported by the transport layer.

Abstract: A method and composition of matter for balancing tire and rim assemblies of vehicles is disclosed wherein the composition of matter has rounded balancing elements of different size to line the interior of a tire casing and to move over the lining to offset points of imbalance.

Abstract: A method and composition of matter for balancing tire and rim assemblies of vehicles is disclosed wherein the composition of matter has rounded balancing elements of different sizes to line the interior of a tire casing and to move over the lining to offset points of imbalance.

Abstract: A method and composition of matter for balancing tire and rim assemblies of vehicles is disclosed wherein the composition of matter has rounded balancing elements of different sizes to line the interior of a tire casing and to move over the lining to offset points of imbalance.

Abstract: A device and method for encouraging proper timing compliance in accordance with a medication prescription regimen. The device is preprogrammed so as to be tailored for the particular prescription regimen to be complied with. Appropriate circuitry is provided in order to generate a dosage signal, which dosage signal persists and changes in an easily recognizable manner until compliance with that dosage requirement is indicated by interacting with the device. Also included is circuitry for prompting compliance with refill requirements of the prescription. The device includes a casing which can have members for facilitating stand-up display or hang-up display of the device.